Rapport Therapeutics CEO sells 2,210 shares
The sales were made under Rule 10b5-1 trading plans adopted on March 27, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Rapport Therapeutics, Inc. Chief Executive Officer Ceesay Abraham sold 2,210 shares of common stock on September 23, 2026, in three transactions: 1,952 shares at a weighted average price of $39.0523, 215 shares at a weighted average price of $39.8602, and 43 shares at $41.0500 per share. The sales were made under Rule 10b5-1 trading plans adopted on March 27, 2026. Abraham's reported indirect holdings included 81,729 shares through Ceesay Family Irrevocable Trust and 20,729 shares through Dorothy Ceesay Irrevocable Trust.
Insider Trade Summary 10b5-1
Net Seller: 2,210 shares
Net Sell
3 txns
Insider
Ceesay Abraham
Role
Chief Executive Officer
Sold
2,210 shs ($87K)
Share of Position Sold
0.48%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 1,952 | $39.0523 | $76K |
| Sale | Common Stock F1, F3 | 215 | $39.8602 | $9K |
| Sale | Common Stock F1 | 43 | $41.05 | $2K |
| Holding | Common Stock | -- | -- | -- |
| Holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 456,767 shares (Direct);
Common Stock — 81,729 shares (Indirect, By Ceesay Family Irrevocable Trust);
Common Stock — 20,729 shares (Indirect, By Dorothy Ceesay Irrevocable Trust)
Holdings Before and After:
Common Stock, 458,977 to 456,767 shares (Direct)
Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (3)
- F1. These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026.
- F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.54 to $39.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.57 to $40.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
Key Figures
Shares sold, transaction 1: 1,952 shares
Weighted average price, transaction 1: $39.0523 per share
Shares sold, transaction 2: 215 shares
+5 more
8 metrics
Shares sold, transaction 1
1,952 shares
September 23, 2026
Weighted average price, transaction 1
$39.0523 per share
September 23, 2026
Shares sold, transaction 2
215 shares
September 23, 2026
Weighted average price, transaction 2
$39.8602 per share
September 23, 2026
Shares sold, transaction 3
43 shares
September 23, 2026
Price, transaction 3
$41.0500 per share
September 23, 2026
Indirect shares through Ceesay Family Irrevocable Trust
81,729 shares
Reported September 23, 2026
Indirect shares through Dorothy Ceesay Irrevocable Trust
20,729 shares
Reported September 23, 2026
Key Terms
Rule 10b5-1 trading plans, weighted average price, Irrevocable Trust
3 terms
Rule 10b5-1 trading plans regulatory
"pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026"
Rule 10b5-1 trading plans are written, pre-arranged instructions that allow company insiders (such as executives or directors) to automatically buy or sell their company's stock at specified times or under set conditions, like a standing instruction or automated thermostat for trades. They matter to investors because these plans provide a legal defense against insider‑trading accusations and create predictable insider trading patterns that can help signal whether sales are routine portfolio management or potentially meaningful to the company’s outlook.
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Irrevocable Trust financial
"By Ceesay Family Irrevocable Trust"
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What price ranges were reported for the RAPP CEO's September 23 sales?
For the 1,952-share transaction, the weighted average price was $39.0523, with sales from $38.54 to $39.48, inclusive. For the 215-share transaction, the weighted average price was $39.8602, with sales from $39.57 to $40.25, inclusive. A separate 43-share transaction was reported at $41.0500 per share.
AI-generated analysis. How Rhea-AI works. Not financial advice.
